Cited by 2,809Heart Failure Treatment and ManagementHormonal Regulation and HypertensionCardiovascular Function and Risk Factors

Spironolactone for heart failure with preserved ejection fraction

Open access
Pitt, Bertram, Pfeffer, Marc A., Assmann, Susan F., Boineau, Robin, Anand, Inder S., Claggett, Brian, Clausell, Nadine, Desai, Akshay S. +15 more·2014·New England Journal of Medicine

Abstract

BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction. METHODS: In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo. The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. RESULTS: With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 to 1.04; P=0.14). Of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard ratio, 0.83; 95% CI, 0.69 to 0.99, P=0.04). Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. Treatment with spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypokalemia. With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher, or dialysis. CONCLUSIONS: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1313731

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Steroidal MRA, such as spironolactone and eplerenone, have established cardiovascular benefits in those with heart failure and are useful for treating primary hyperaldosteronism and refractory hypertension.

    “Steroidal MRA, such as spironolactone and eplerenone, have established cardiovascular bene fi ts in those with heart failure and are useful for treating primary hyperaldosteronism and refractory hypertension.”

    From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [156]

    The Background and Conclusions passages state that mineralocorticoid-receptor antagonists improve outcomes in heart failure with reduced ejection fraction. The paper does not establish their usefulness for primary hyperaldosteronism or refractory hypertension; its Discussion also reports that spironolactone did not significantly reduce the primary outcome in heart failure with preserved ejection fraction. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Steroidal MRA are standard of care for treatment of heart failure (particularly with reduced ejection fraction) and primary hyperaldosteronism.

    “Steroidal MRA are standard of care for treatment of heart failure (particularly with reduced ejection fraction) and primary hyperaldosteronism.”

    From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [156]

    The Background and Conclusions (page not provided) state that mineralocorticoid-receptor antagonists improve outcomes in heart failure with reduced ejection fraction. The paper does not address their use for primary hyperaldosteronism, and its trial found no significant reduction in the primary outcome for heart failure with preserved ejection fraction. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Steroidal MRA are useful for management of heart failure as well as primary hyperaldosteronism and resistant hypertension.

    “Steroidal MRA are useful for management of heart failure as well as primary hyperaldosteronism and resistant hypertension.32,33”
  • Clinical trial results are somewhat conflicting regarding the risk of all-cause and cardiovascular mortality attributed to T2DM in HF patients, but most clinical trials reported an increased risk of death in patients with concurrent T2DM and HF.

    “Clinical trial results are somewhat conflicting regarding the risk of all-cause and CV mortality attributed to T2DM in HF patients, but most clinical trials reported an increased risk of death in patients with concurrent T2DM and HF (Table 5).1,31 -35,37,40,42,44,45,69,88-92”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Braunwald E. Heart failure: an up- date. Clin Pharmacol Ther 2013;94:430-2.
  2. Shah SJ, Gheorghiade M. Heart fail- ure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008;300:431-3.

Cited by

Sorted by citations

Authors
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O'Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., Solomon, S. D., Sweitzer, N. K., Yang, S., & McKinlay, S. M.
Affiliations
  • Brigham and Women's Hospital (US)
  • New England Research Institutes (US)
  • National Heart, Lung, and Blood Institute (US)
  • University of Minnesota (US)
  • Hospital de Clínicas de Porto Alegre (BR)
  • Pirogov Russian National Research Medical University (RU)
  • NewYork–Presbyterian Brooklyn Methodist Hospital (US)
  • University of Washington Medical Center (US)
  • Georgian National Museum (GE)
  • Northwestern University (US)
  • University of Wisconsin–Madison (US)
Venue
New England Journal of Medicine
Published
2014-04-10
Volume
370
Issue
15
Pages
1383-1392
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2152072062
Cited by
2,809
References
39
Citations by year
2026: 226 · 2025: 262 · 2024: 238 · 2023: 231 · 2022: 308 · 2021: 277 · 2020: 254 · 2019: 210 · 2018: 210 · 2017: 200 · 2016: 149 · 2015: 161 · 2014: 78 · 2013: 2
FWCI
134.42
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (HHSN268200425207C)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
spironolactone, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, cardiovascular mortality, heart failure hospitalization, hyperkalemia, serum creatinine, TOPCAT trial, adverse events, left ventricular ejection fraction, dialysis, cardiac arrest, renin-angiotensin system blockade, renin-angiotensin-aldosterone system inhibitors
MeSH terms
Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Spironolactone, Stroke Volume, Incidence, Treatment Failure, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review